September 5, 2024 - Written by Aiforia
Assistance Publique–Hôpitaux de Paris (AP-HP) has selected Aiforia Technologies Plc as a partner for AI-assisted pathology image analysis in clinical diagnostics. aa partner for AI-assisted pathology image analysis in clinical diagnostics.
Aiforia Technologies Plc, Press Release, September 5, 2024 at 09:00 a.m. EEST
Assistance Publique–Hôpitaux de Paris (AP-HP) has selected Aiforia Technologies Plc as a partner for AI-assisted pathology image analysis in clinical diagnostics. The collaboration involves the use of the Aiforia Clinical AI solutions for the analysis of tissue samples from prostate cancer patients.
“The department of Pathology in Bicetre hospital (AP-HP Paris Saclay University) has been a pilot site in France for digital pathology since 2018. The next step was to be among the early adopters of artificial intelligence. The screening of prostate biopsies seemed to us to be an excellent indication to implement a first AI algorithm in our routine. The department of Pathology of Saint-Louis hospital (AP-HP University Paris Cité) joined us in this project financially supported by the regional Health Agency of Ile de France. Our benchmarking approach led us to choose the solution proposed by Aiforia because of the performance observed during tests carried out using our own WSI and the way the AI results are presented. This project will allow the AP-HP to prepare the dissemination of AI in all of its pathology departments,” says Catherine Guettier, Head of Department of Pathological Anatomy and Cytology of AP-HP.
“We're honored to have another world-leading hospital choose us as their partner. These first steps with AP-HP carry immense strategic importance for Aiforia, and there are exciting opportunities for expanding the collaboration in the future,” says Jukka Tapaninen, CEO of Aiforia.
The AP-HP is a world-renowned university hospital center consisting of 38 hospitals in Paris and its surroundings and receives 8 million annual patient visits.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plctel. +33 61 041 6686https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltdubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient. Find out more at www.aiforia.com artner for AI-assisted pathology image analysis in clinical diagnostics.